Black Rock Inc. Albireo Pharma, Inc. Transaction History

Black Rock Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	BUY	$18.01 - $23.78 $2.33 Million - $3.08 Million	129,491 Added 10.65%	1,344,897 $29.1 Million
Q3 2022 Nov 14, 2022	BUY	$16.32 - $26.37 $45,467 - $73,466	2,786 Added 0.23%	1,215,406 $23.5 Million
Q2 2022 Aug 12, 2022	BUY	$18.54 - $37.29 $1.14 Million - $2.3 Million	61,588 Added 5.35%	1,212,620 $24.1 Million
Q1 2022 May 12, 2022	SELL	$23.94 - $33.74 $424,958 - $598,918	-17,751 Reduced 1.52%	1,151,032 $34.3 Million
Q4 2021 Feb 10, 2022	BUY	$21.19 - $31.29 $252,521 - $372,882	11,917 Added 1.03%	1,168,783 $27.2 Million

Q3 2021 Nov 09, 2021	SELL	$27.36 - $35.98 $1.15 Million - $1.51 Million	-41,956 Reduced 3.5%	1,156,866 $36.1 Million
Q2 2021 Aug 11, 2021	BUY	$28.9 - $36.87 $34.6 Million - $44.2 Million	1,198,822 New	1,198,822 $42.2 Million

865

Ticker ALBO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 19,612,500
Description
Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as we...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.